May 17 | 2022

Three IndiTreat® posters have been accepted at ESMO-GI 2022

Read more
May 12 | 2022

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

Read more
May 12 | 2022

2cureX AB nominerar Dr. Michael Schaefer till styrelsen

Read more
May 11 | 2022

IGNITE update – Eight hospitals have been enrolled in the program

Read more
May 9 | 2022

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

Read more
May 6 | 2022

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

Read more
May 6 | 2022

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

Read more
May 5 | 2022

Redeye research interview with 2cureX CEO, Fernando Andreu

Read more
May 3 | 2022

2cureX offentliggör årsredovisning för räkenskapsåret 2021

Read more
May 3 | 2022

2cureX publishes the annual report for the fiscal year 2021

Read more
April 29 | 2022

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Read more
April 22 | 2022

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022

Read more
April 22 | 2022

Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Read more
April 21 | 2022

Kallelse till årsstämma i 2cureX AB

Read more
April 21 | 2022

Notice of annual general meeting of 2cureX AB (publ)

Read more
April 21 | 2022

Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.

Read more
April 14 | 2022

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Read more
March 15 | 2022

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Read more